Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective
Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm.
Source: Urology - Category: Urology & Nephrology Authors: Madeline Cancian, Joseph F. Renzulli Tags: Review Article Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | CT Scan | Food and Drug Administration (FDA) | PET Scan | Prostate Cancer | Urology & Nephrology